0245 GMT December 14, 2019
Preliminary results from the ongoing, multicenter study were included in the press program here today at the 59th annual meeting of the American Society of Hematology, medicalxpress.com reported.
Approximately four months after treatment, five of the seven patients enrolled in the St. Jude clinical trial had immune systems for the first time.
The patients no longer require protective isolation. Four patients have started making serum immunoglobulins (antibodies) for the first time. One has stopped monthly immunoglobulin supplementation and recently received his first set of vaccinations.
Ewelina Mamcarz, MD, an assistant member of the St. Jude Department of Bone Marrow Transplantation and Cellular Therapy, said, "These results are an exciting early indication that this gene therapy is well tolerated and effective in infants as young as 2 months old with this devastating inherited immune disorder.”
Immune protection will likely return to the last patient. There is evidence that the seventh patient, who joined the study six weeks ago, now carries the vector in his immune cells.
No serious or unexpected treatment-related complications have been reported.
The results are the first involving infants with XSCID treated with the St. Jude lentiviral vector.
Researchers previously reported promising results in adolescents and young adults with XSCID who were treated with the St. Jude vector and low-dose chemotherapy after bone marrow transplantation failed to restore adequate immune protection.
The patients in this study were between the ages of two and 13 months and born with a disorder caused by a mutation in the IL2RG gene.
The mutation primarily affects boys and leaves them with little or no immune protection.
The disorder is also known as ‘bubble boy’ disease, a reference to the measures used to protect patients from infections and other threats. Untreated, individuals usually die of overwhelming infections within months.
Currently, transplantation with a tissue-matched sibling donor is the standard treatment for XSCID.
More than 80 percent of XSCID patients, including the infants in this study, do not have matched sibling donors.
These patients must rely on unrelated donors or parent donors, who are partial genetic matches.
Such transplants are less likely to fully restore immune function and are associated with potentially severe treatment-related complications.
In response, St. Jude researchers have re-engineered a lentivirus to function as a vector to ferry a normal copy of IL2RG into the patients' hematopoietic stem cells.
The vector includes novel features to enhance safety and effectiveness. The features include genetic insulators to block activation of genes adjacent to the IL2RG DNA insertion site.
The design aims to ensure gene therapy will not lead to leukemia by inadvertently activating an oncogene in the patient's hematopoietic stem cells.
The treatment involves removing the patient's bone marrow and letting the hematopoietic stem cells incubate with the lentiviral vector carrying the normal gene.
The stem cells are then processed and returned to the patient via transfusion.
Prior to transfusion, patients receive low-dose chemotherapy with the drug busulfan. Unlike the prior studies, the level of busulfan in the patient's blood is pharmacologically targeted to avoid variability in blood levels and improve safety.
The chemotherapy is designed to make space in the bone marrow for the gene-corrected hematopoietic stem cells to settle in and start working.
Brian Sorrentino, MD, a member of the St. Jude Department of Hematology, who leads this study with Mamcarz, said, "These early results in infants reinforce hope that gene therapy will prove to be safe and effective at restoring immune function early in life.”
Following gene therapy, levels of T, B and natural killer cells rose to near normal levels in five of the first six patients who enrolled in the study.
The vast majority of the immune cells, including 100 percent of the T and natural killer cells, carried the normal gene that was carried in the lentiviral vector. 60 to 80 percent of the B cells also carried the normal gene.
Previous gene therapy for XSCID did not lead to such high levels of genetic correction in all immune cell types.
In three of the five patients, 50 percent or more of the hematopoietic stem cells also carried the normal gene.
Mamcarz said, "This suggests these patients will likely enjoy life-long immune protection without exposure to high-dose chemotherapy.”
This level of bone marrow stem cell correction has not been achieved in prior gene therapy studies in XSCID infants.
The sixth patient included in the report received a booster dose of gene-corrected blood stem cells.
Laboratory tests indicate T cells, including T cells with the correct gene, have begun to increase.
Mamcarz said, "This was a complex patient.”
The patient was being treated for severe neutropenia and a viral infection when he joined the study.
In addition, maternal T cells had engrafted in his bone marrow, complicating efforts to restore his own genetically corrected blood stem cells to his bone marrow.